Palisade Bio shares surge 10.05% premarket after first patients dosed in Phase 1b study of PALI-2108 for Crohn's disease.

Palisade Bio (NASDAQ:PALI) surged 10.05% in premarket trading following the announcement of a strategic equity investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to advance its lead candidate, PALI-2108. This investment, disclosed on January 7, 2026, signals institutional validation of the drug’s potential in treating fibrostenotic Crohn’s disease, a key unmet medical need. The move builds on prior milestones, including the initiation of a Phase 1b study for PALI-2108 in October 2025 and recent patent grants in Japan and Canada, which strengthen intellectual property protections. The funding partnership likely bolstered investor confidence by de-risking development costs and highlighting the program’s therapeutic promise, directly aligning with the stock’s sharp premarket rise.